{
  
  "resourceType": "StructureDefinition",
  "id": "AdverseReactionRiskSummary",
  "url": "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRiskSummary",
  "name": "AdverseReactionRiskSummary",
  "title": "Adverse Reaction Risk Summary",
  "status": "draft",
  "experimental": false,
  "publisher": "CSIRO",
  "description": "The Adverse Reaction Risk Summary Logical Model Mindmap is shown below.\n\n<div><img src='data:image/png;base64,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'/></div>\n\nAn adverse reaction risk is a risk of a harmful or undesirable physiological reaction, which is unique to the individual and associated with exposure to a known substance.\n\n**Purpose**\n\nTo record an assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances, and an overview of each related reaction event.\n\n**Supported Models**\n\nAdverse reaction risk, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10].\nAvailable from: [https://ckm.openehr.org/ckm/archetypes/1013.1.7022](https://ckm.openehr.org/ckm/archetypes/1013.1.7022).\n\nAdverse reaction event, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10].\nAvailable from: [https://ckm.openehr.org/ckm/archetypes/1013.1.5795](https://ckm.openehr.org/ckm/archetypes/1013.1.5795).\n\nAllergyIntolerance, HL7 FHIR Resource [Internet]. Health Level Seven International; [accessed 2023 Dec 10].\nAvailable from: [https://hl7.org/fhir/R5/allergyintolerance.html](https://hl7.org/fhir/R5/allergyintolerance.html).\n\n**Considerations**\n\n* It is anticipated that this data group will be expanded over time to incorporate additional detail about the propensity and each reaction event.\n* Each adverse reaction risk summary can be included within a curated Adverse reaction or Allergy list (or similar).\n* Substances include, but are not limited to, a therapeutic substance administered correctly at an appropriate dosage for the individual; food; material derived from plants or animals; or venom from insect stings.\n* This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\n  * immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or\n  * non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities in individuals with impaired excretion.",
  "keyword": [
    {
      "system": "https://aehrc.csiro.au/fhir/CodeSystem/cdi-category",
      "code": "core"
    }
  ],
  "fhirVersion": "4.0.1",
  "kind": "logical",
  "abstract": false,
  "type": "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRiskSummary",
  "baseDefinition": "http://hl7.org/fhir/StructureDefinition/Base",
  "derivation": "specialization",
  "differential": {
    "element": [
      {
        "id": "AdverseReactionRisk",
        "extension": [
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-purpose",
            "valueString": "To record an assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances, and an overview of each related reaction event."
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString": "* It is anticipated that this data group will be expanded over time to incorporate additional detail about the propensity and each reaction event.\n* Each adverse reaction risk summary can be included within a curated Adverse reaction or Allergy list (or similar).\n* Substances include, but are not limited to, a therapeutic substance administered correctly at an appropriate dosage for the individual; food; material derived from plants or animals; or venom from insect stings.\n* This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\n  * immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or\n  * non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities in individuals with impaired excretion."
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-mapping",
            "valueString": "Adverse reaction risk, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10].\nAvailable from: [https://ckm.openehr.org/ckm/archetypes/1013.1.7022](https://ckm.openehr.org/ckm/archetypes/1013.1.7022).\n\nAdverse reaction event, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10].\nAvailable from: [https://ckm.openehr.org/ckm/archetypes/1013.1.5795](https://ckm.openehr.org/ckm/archetypes/1013.1.5795).\n\nAllergyIntolerance, HL7 FHIR Resource [Internet]. Health Level Seven International; [accessed 2023 Dec 10].\nAvailable from: [https://hl7.org/fhir/R5/allergyintolerance.html](https://hl7.org/fhir/R5/allergyintolerance.html)."
          }
        ],
        "path": "AdverseReactionRiskSummary",
        "short": "Adverse Reaction Risk Summary",
        "definition": "An adverse reaction risk is a risk of a harmful or undesirable physiological reaction, which is unique to the individual and associated with exposure to a known substance.",
        "comment": "**Purpose**\n\nTo record an assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances, and an overview of each related reaction event.\n\n**Supporting Model(s)**\n\nAdverse reaction risk, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10].\nAvailable from: [https://ckm.openehr.org/ckm/archetypes/1013.1.7022](https://ckm.openehr.org/ckm/archetypes/1013.1.7022).\n\nAdverse reaction event, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10].\nAvailable from: [https://ckm.openehr.org/ckm/archetypes/1013.1.5795](https://ckm.openehr.org/ckm/archetypes/1013.1.5795).\n\nAllergyIntolerance, HL7 FHIR Resource [Internet]. Health Level Seven International; [accessed 2023 Dec 10].\nAvailable from: [https://hl7.org/fhir/R5/allergyintolerance.html](https://hl7.org/fhir/R5/allergyintolerance.html).\n\n**Considerations**\n\n* It is anticipated that this data group will be expanded over time to incorporate additional detail about the propensity and each reaction event.\n* Each adverse reaction risk summary can be included within a curated Adverse reaction or Allergy list (or similar).\n* Substances include, but are not limited to, a therapeutic substance administered correctly at an appropriate dosage for the individual; food; material derived from plants or animals; or venom from insect stings.\n* This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\n  * immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or\n  * non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities in individuals with impaired excretion.",
        "alias": [
          "Adverse reaction",
          "allergy",
          "intolerance",
          "hypersensitivity"
        ],
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "BackboneElement"
          }
        ]
      },
      {
        "id": "AdverseReactionRisk.Substance",
        "extension": [
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-example",
            "valueString": "111088007 | Latex\n256259004 | Pollen\n102263004 | Eggs (edible)\n256349002 | Peanut\n373270004 | Penicillin\n3738011000036101 | Amoxil"
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString": "This ADHA value set contains a broad set to support the recording of agents that may be responsible for causing adverse reactions.  This set includes all AMT product Clinicals as well as SNOMED CT-AU substances such as chemical, material and dietary substances"
          }
        ],
        "path": "AdverseReactionRiskSummary.SubstanceName",
        "short": "Substance Name",
        "definition": "Identification of a substance, or substance class, which is considered to put the individual at risk of an adverse reaction event. \nBoth an individual substance and a substance class are valid entries in Substance. A substance may be a compound of simpler substances, for example a medicinal product.",
        "comment": "**Considerations**\n\nThis ADHA value set contains a broad set to support the recording of agents that may be responsible for causing adverse reactions.  This set includes all AMT product Clinicals as well as SNOMED CT-AU substances such as chemical, material and dietary substances\n\n**Example**\n\n111088007 | Latex\n256259004 | Pollen\n102263004 | Eggs (edible)\n256349002 | Peanut\n373270004 | Penicillin\n3738011000036101 | Amoxil",
        "alias": [
          "Agent",
          "Class",
          "Product"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "CodeableConcept"
          }
        ]
      },
      {
        "id": "AdverseReactionRisk.Manifestation",
        "extension": [
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString": "This AEHRC value set contains the ADHA developed Clinical manifestation reference set, which contains SNOMED CT-AU Clinicals that can be used to describe manifestations.\n\nt is strongly recommended that\n‘Manifestation’ be coded with a terminology\ncapable of triggering decision support,\nwhere possible. Free text entry should only\nbe permitted if there is no appropriate\nterminology available"
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-example",
            "valueString": "39579001 | Anaphylaxis |\n126485001 | Urticaria |\n267038008 | Oedema |\n62315008 | Diarrhoea |\n422587007 | Nausea |"
          }
        ],
        "path": "AdverseReactionRiskSummary.Manifestation",
        "short": "Manifestation",
        "definition": "Symptom or sign observed or associated with the reaction.",
        "comment": "**Considerations**\n\nThis AEHRC value set contains the ADHA developed Clinical manifestation reference set, which contains SNOMED CT-AU Clinicals that can be used to describe manifestations.\n\nt is strongly recommended that\n‘Manifestation’ be coded with a terminology\ncapable of triggering decision support,\nwhere possible. Free text entry should only\nbe permitted if there is no appropriate\nterminology available\n\n**Example**\n\n39579001 | Anaphylaxis |\n126485001 | Urticaria |\n267038008 | Oedema |\n62315008 | Diarrhoea |\n422587007 | Nausea |",
        "alias": [
          "Reaction",
          "Nature of reaction",
          "Clinical manifestation"
        ],
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "CodeableConcept"
          }
        ]
      },
      {
        "id": "AdverseReactionRisk.Comment",
        "path": "AdverseReactionRiskSummary.Comment",
        "short": "Comment",
        "definition": "Additional narrative about the adverse reaction risk not captured in other fields.",
        "alias": [
          "Note"
        ],
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "string"
          }
        ]
      }
    ]
  }
}
